AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Calquence (acalabrutinib) by Year
Calquence (acalabrutinib) — Worldwide product sales ($M) ($M)
AstraZeneca Calquence (acalabrutinib): $3,518M in FY2025, up 12.4% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Calquence | 3,518 | 12 | 12 | 2,339 | 7 | 233 | 52 | 54 | 784 | 20 | 15 | 162 | 25 | 27”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Calquence (acalabrutinib) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,518 | +12.4% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 3,129 | +24.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 2,514 | +22.2% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 2,057 | +66.2% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1,238 | +137.2% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 522 | +218.3% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 164 | +164.5% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 62 | +1,966.7% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 3 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up calquence (acalabrutinib)
- Calquence (acalabrutinib) — Worldwide YoY actual (%)12.0% · FY2025
- Calquence (acalabrutinib) — Worldwide YoY CER (%)12.0% · FY2025
- Calquence (acalabrutinib) — US product sales ($M)2,339 · FY2025
- Calquence (acalabrutinib) — Emerging Markets product sales ($M)233 · FY2025
- Calquence (acalabrutinib) — Europe product sales ($M)784 · FY2025
- Calquence (acalabrutinib) — Established RoW product sales ($M)162 · FY2025
Cite this data
StockData. (2026). AstraZeneca Calquence (acalabrutinib) ($M), annual FY2017–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-calquence-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.